Drug Profile
Gumokimab - Akeso Biopharma
Alternative Names: AK-111Latest Information Update: 29 Dec 2023
Price :
$50
*
At a glance
- Originator Akeso Biopharma
- Class Anti-inflammatories; Antipsoriatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin-17 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Plaque psoriasis
- Phase II Ankylosing spondylitis
Most Recent Events
- 14 Sep 2023 Akeso initiates a phase II trial for Plaque psoriasis in China (SC) (NCT06061471)
- 31 Mar 2023 Phase-III clinical trials in Plaque psoriasis in China (SC) (NCT06066125)
- 01 Feb 2023 Akeso completes phase II trial in Plaque psoriasis (Treatment resistant) in China (SC) (NCT05096364)